Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults (Q27756): Difference between revisions
Jump to navigation
Jump to search
Superraptor (talk | contribs) (Changed claim: author (P72): Arjee Restar (Q27744)) |
Superraptor (talk | contribs) (Added [en] label: Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults) |
||
| label / en | label / en | ||
Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults | |||
Latest revision as of 19:30, 28 October 2024
No description defined
- Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults |
No description defined |
|
Statements
Integrating gender-affirming care with biomedical HIV prevention could help address the disproportionate HIV risk experienced by transgender and nonbinary (trans) adults. (English)
© 2024. The Author(s). (English)
2024
This discrete choice experiment assesses and identifies the most important programming factors influencing the decisions of trans adults to use injectable long-acting HIV pre-exposure prophylaxes (LA-PrEP). (English)
© 2024. The Author(s). (English)
2024
From March to April 2023 n = 366 trans adults in Washington state chose between four different choice profiles that presented hypothetical programs (each comprised of 5 attributes with 4 levels). (English)
© 2024. The Author(s). (English)
2024
We analyzed ranked choice responses using a mixed rank-ordered logit model for main effects. (English)
© 2024. The Author(s). (English)
2024
Respondents preferred to receive LA-PrEP from a gender-affirming care provider and a co-prescription for both oral and injectable hormones. (English)
© 2024. The Author(s). (English)
2024
Trans adults strongly favored 12-month protection and injection in the upper arm. (English)
© 2024. The Author(s). (English)
2024
No strong preferences emerged surrounding the type of health facility offering the gender-affirming LA-PrEP program. (English)
© 2024. The Author(s). (English)
2024
Our findings show that integrating and leveraging gender-affirming health systems, inclusive of medical services such as hormone therapy, with HIV biomedical products like LA-PrEP is strongly preferred and influential to trans adults' decision to use LA-PrEP. (English)
© 2024. The Author(s). (English)
2024
Leveraging choice-based design experiments provides informative results for optimizing gender-affirming LA-PrEP programming tailored to trans adults. (English)
© 2024. The Author(s). (English)
2024
M G (English)
Wilson-Barthes (English)
MG
D (English)
Operario (English)
D
O (English)
Galárraga (English)
O
11 October 2024
8 October 2024